Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clene Inc. filings document regulatory, financing, governance and operating disclosures for a late clinical-stage biopharmaceutical company focused on neurodegenerative diseases. Form 8-K reports cover CNM-Au8 clinical and regulatory communications, operating and financial results, securities purchase agreements, warrant terms and grant-related subaward agreements supporting ALS expanded access activity.
Proxy materials describe annual meeting proposals, director elections, auditor ratification and other shareholder voting matters. The filing record also addresses capital-structure changes, material agreements, Regulation FD disclosures, intellectual-property provisions tied to research funding, clinical and regulatory disclosures, and the role of Clene Nanomedicine Inc. in the company’s development programs.
Clene Inc. (CLNN) reported a director equity award on Form 4. On November 13, 2025, the director received a stock option covering 2,438 shares of common stock at an exercise price of $7.30 per share under the Clene Inc. Amended 2020 Stock Plan. The option vests immediately upon grant and carries an expiration date of November 12, 2035.
The filing classifies the transaction as an acquisition of derivative securities and lists direct ownership following the grant.
Clene Inc. (CLNN) reported an insider equity award. A director filed a Form 4 disclosing a stock option grant for 2,887 shares of common stock at an exercise price of $7.30 per share on November 13, 2025. The options vest immediately upon grant under the Clene Inc. Amended 2020 Stock Plan and carry an expiration date of November 12, 2035. Following the transaction, the filing shows 2,887 derivative securities beneficially owned with direct ownership.
Clene Inc. (CLNN) reported a stock-based compensation award to one of its directors. On November 13, 2025, the director received a stock option covering 2,816 shares of Clene common stock under the company’s Amended 2020 Stock Plan. The option has an exercise price of $7.30 per share and vests immediately, meaning the director can exercise it right away, subject to plan terms. The option is scheduled to expire on November 12, 2035 if not exercised.
Clene Inc. (CLNN) reported a routine insider transaction: a director received a stock option grant for 1,893 shares on 11/13/2025 under the Amended 2020 Stock Plan at an exercise price of $7.30 per share.
The options vest immediately upon grant and expire on 11/12/2035. Ownership of the derivative securities is reported as direct.
Clene Inc. furnished an 8-K announcing third quarter 2025 financial results and recent operating highlights for the quarter ended September 30, 2025. The details are provided in a press release furnished as Exhibit 99.1 and incorporated by reference. The Item 2.02 information is furnished, not filed, and is not subject to Section 18 liabilities. The filing also lists the company’s Nasdaq-listed common stock (CLNN) and warrants (CLNNW).
Clene Inc. reported Q3 2025 results highlighting limited revenue and continued losses. Total revenue was $15 thousand (product $0, royalty $15 thousand). Loss from operations was $5.6 million, and net loss was $8.8 million (basic and diluted EPS $(0.85)).
Cash and cash equivalents were $7.9 million at September 30, 2025, down from $12.2 million at year-end. Net cash used in operating activities for the nine months was $13.7 million. The company reported a stockholders’ deficit of $12.4 million. Management stated that conditions “raise substantial doubt” about the ability to continue as a going concern, including a covenant to maintain at least $2.0 million of unrestricted cash under the 2024 senior secured convertible notes.
To support liquidity, Clene raised $3.3 million via its equity distribution agreement during Q3 and $1.5 million from new senior secured convertible notes, and subsequently generated $1.2 million more from the equity distribution. Shares outstanding were 10,333,980 as of November 10, 2025. Grant funding reduced expenses by $2.3 million (R&D) and $0.1 million (G&A) in the quarter.
Clene Inc. (CLNN) expanded its at-the-market equity program. The company previously entered into an equity distribution agreement to offer and sell common stock with an aggregate offering price of up to $25,000,000 through Canaccord Genuity LLC.
As of October 17, 2025, Clene reported prior sales of approximately $6,119,859 under this program and filed a prospectus supplement covering an additional $18,880,000 of common stock. A legal opinion from Holland & Knight LLP regarding the validity of the shares was filed as Exhibit 5.1.
Clene Inc. may offer and sell shares of common stock with a maximum aggregate gross sales price of up to $18,880,000 from time to time through Canaccord Genuity under its at‑the‑market program, as updated by Prospectus Supplement No. 3.
This amount excludes $6,119,859 of shares sold under prior supplements to date. Clene will receive the proceeds from any sales, and Canaccord may receive a commission of up to 3.0% of the gross sales price per share. The company notes it is no longer subject to the General Instruction I.B.6 sales limitations for its S‑3. On October 15, 2025, Nasdaq reported last sale prices of $8.89 for CLNN and $0.0102 for CLNNW.
Clene Inc. (CLNN) furnished an updated corporate presentation that includes preliminary unaudited figures for its cash and cash equivalents as of September 30, 2025, and the gross proceeds raised under its at-the-market equity distribution agreement from after September 30, 2025 through October 14, 2025. The presentation is attached as Exhibit 99.1.
The company notes these figures were prepared by management and remain subject to completion of financial closing procedures and potential audit adjustments. The materials are furnished under Items 2.02 and 7.01 and are not deemed “filed” for purposes of Section 18 of the Exchange Act, which means they are not subject to its liability provisions or automatically incorporated by reference into other filings.
Clene Inc. reporting person Mark Mortenson (Chief Science Officer) filed an amended Form 4 correcting an earlier filing to show an option grant for 40,000 shares of common stock. The option was granted 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan with a corrected exercise price of $5.88 per share. The options vest in 12 equal monthly installments beginning 10/25/2025 and expire 09/24/2035. The amendment clarifies the exercise price only; no other transactions or changes in beneficial ownership are reported.